{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:57:59Z","timestamp":1790539079196,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032339","name":"BioNTech","doi-asserted-by":"publisher","award":["164\\u2013024781\/0051"],"award-info":[{"award-number":["164\\u2013024781\/0051"]}],"id":[{"id":"10.13039\/100032339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-004737"],"award-info":[{"award-number":["INV-004737"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-035506"],"award-info":[{"award-number":["INV-035506"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014895","name":"Coefficient Giving LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001411","name":"Myriad USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000269","name":"Economic and Social Research Council","doi-asserted-by":"publisher","award":["ES\/P008011\/1"],"award-info":[{"award-number":["ES\/P008011\/1"]}],"id":[{"id":"10.13039\/501100000269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Marathon Foundation of Tv3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["2020\/985800\\u20130"],"award-info":[{"award-number":["2020\/985800\\u20130"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101001038"],"award-info":[{"award-number":["101001038"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101,117,940"],"award-info":[{"award-number":["101,117,940"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006282","name":"Koning Boudewijnstichting","doi-asserted-by":"publisher","award":["2025- I4242220\\u20130025486"],"award-info":[{"award-number":["2025- I4242220\\u20130025486"]}],"id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["G-202303-69,963"],"award-info":[{"award-number":["G-202303-69,963"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R-202309-71,190"],"award-info":[{"award-number":["R-202309-71,190"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI147321\\u201301"],"award-info":[{"award-number":["1R01AI147321\\u201301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA101249120"],"award-info":[{"award-number":["RIA101249120"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2018D-2511"],"award-info":[{"award-number":["RIA2018D-2511"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA101190731"],"award-info":[{"award-number":["RIA101190731"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["310,728\/Z\/24\/Z"],"award-info":[{"award-number":["310,728\/Z\/24\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218261\/Z\/19\/Z"],"award-info":[{"award-number":["218261\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020392","name":"Good Ventures Foundation","doi-asserted-by":"publisher","award":["GV673606227"],"award-info":[{"award-number":["GV673606227"]}],"id":[{"id":"10.13039\/100020392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI182647"],"award-info":[{"award-number":["K24AI182647"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129097","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:13:46Z","timestamp":1788221626000},"page":"129097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluating the influence of vaccine archetypes and epidemiological conditions on clinical trial metrics for tuberculosis vaccine candidates"],"prefix":"10.1016","volume":"91","author":[{"given":"Jason R.","family":"Andrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto L.","family":"Garc\u00eda-Basteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Croda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cobelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129097_bb0005","series-title":"Global Tuberculosis Report 2025","author":"World Health Organization","year":"2025"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129097_bb0010","doi-asserted-by":"crossref","first-page":"e1307","DOI":"10.1016\/S2214-109X(22)00283-2","article-title":"Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis","volume":"10","author":"Martinez","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129097_bb0015","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2214-109X(23)00045-1","article-title":"The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study","volume":"11","author":"Clark","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"25","key":"10.1016\/j.vaccine.2026.129097_bb0020","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129097_bb0025","article-title":"How a big pharma company stalled a potentially lifesaving vaccine in pursuit of bigger profits","author":"Barry-Jester","year":"2023","journal-title":"ProPublica October"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129097_bb0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129097_bb0035","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/S2468-2667(21)00025-6","article-title":"Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis","volume":"6","author":"Cords","year":"2021","journal-title":"Lancet Public Health"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129097_bb0040","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2468-2667(23)00097-X","article-title":"Global, regional, and national estimates of tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a systematic analysis","volume":"8","author":"Martinez","year":"2023","journal-title":"Lancet Public Health"},{"issue":"20","key":"10.1016\/j.vaccine.2026.129097_bb0045","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMp2025955","article-title":"Covid-19 vaccine trials and incarcerated people \u2014 the ethics of inclusion","volume":"383","author":"Strassle","year":"2020","journal-title":"New England Journal of Medicine."},{"key":"10.1016\/j.vaccine.2026.129097_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00305-6","article-title":"The participation of people deprived of liberty in tuberculosis vaccine trials: should they be protected from research, or through research?","volume":"25","author":"Andrews","year":"2025","journal-title":"Lancet Infect Dis."},{"issue":"11","key":"10.1016\/j.vaccine.2026.129097_bb0060","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/S2468-2667(24)00192-0","article-title":"Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected effects of policy alternatives: a mathematical modelling study","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Public Health"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129097_bb0065","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/aje\/kwae379","article-title":"Thirty-five years of leaky vaccines","volume":"194","author":"Halloran","year":"2024","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.129097_bb0070","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/813789","article-title":"Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis","volume":"2014","author":"Edlefsen","year":"2014","journal-title":"Comput Math Methods Med"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129097_bb0075","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1093\/cid\/ciaa340","article-title":"Waning of measured influenza vaccine effectiveness over time: the potential contribution of leaky vaccine effect","volume":"71","author":"Tokars","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129097_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40750-8","article-title":"Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population","volume":"14","author":"Lind","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129097_bb0085","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nm0895-815","article-title":"The intrinsic transmission dynamics of tuberculosis epidemics","volume":"1","author":"Blower","year":"1995","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129097_bb0090","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S1473-3099(18)30134-8","article-title":"Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions","volume":"18","author":"Menzies","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129097_bb0095","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis","volume":"54","author":"Andrews","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129097_bb0110","article-title":"Estimating the global burden of viable Mycobacterium tuberculosis infection","author":"Schwalb","year":"2024","journal-title":"Social science research Network Preprint"},{"key":"10.1016\/j.vaccine.2026.129097_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijid.2022.05.029","article-title":"Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990\u20132019","volume":"122","author":"Ding","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129097_bb0130","first-page":"331","article-title":"Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa","volume":"15","author":"Mahomed","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129097_bb0140","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1473-3099(22)00149-9","article-title":"Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017\u201319: a multistage, cluster-based, cross-sectional survey","volume":"22","author":"Moyo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129097_bb0135","series-title":"56th Union World Conference on Lung Health","first-page":"18","article-title":"Intensive screening reduces tuberculosis transmission over time in prisons. Abstract LB03-1330-21","author":"Bampi","year":"2025"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129097_bb0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0041-3879(82)80013-5","volume":"63","author":"Sutherland","year":"1982","journal-title":"Tubercle"},{"issue":"20","key":"10.1016\/j.vaccine.2026.129097_bb0105","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129097_bb0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2334-11-156","article-title":"Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study","volume":"11","author":"Middelkoop","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129097_bb0125","first-page":"406","article-title":"Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa","volume":"14","author":"Wood","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129097_bb0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93+GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.129097_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-015-0764-8","article-title":"Active and latent tuberculosis in Brazilian correctional facilities: a cross-sectional study","volume":"15","author":"Carbone","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2026.129097_bb0155","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129097_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127301","article-title":"Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants","volume":"61","author":"Cobelens","year":"2025","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.vaccine.2026.129097_bb0165","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1016\/j.vaccine.2012.08.045","article-title":"Distinguishing vaccine efficacy and effectiveness","volume":"30","author":"Shim","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129097_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/srep15468","article-title":"Vaccination programs for endemic infections: modelling real versus apparent impacts of vaccine and infection characteristics","volume":"5","author":"Ragonnet","year":"2015","journal-title":"Sci Rep"},{"issue":"10301","key":"10.1016\/j.vaccine.2026.129097_bb0175","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129097_bb0180","doi-asserted-by":"crossref","first-page":"106719","DOI":"10.1016\/j.jinf.2026.106719","article-title":"Effectiveness of the TYPHIBEV\u00ae (Vi-CRM197 conjugate) vaccine introduction in Nepal: a test-negative, case-control study","volume":"92","author":"Tamrakar","year":"2026","journal-title":"Journal of Infection"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129097_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001540","article-title":"Complexity in mathematical models of public health policies: a guide for consumers of models","volume":"10","author":"Basu","year":"2013","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129097_bb0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","article-title":"Interferon-\u03b3 release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis","volume":"37","author":"Diel","year":"2011","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129097_bb0195","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","article-title":"Interferon-\u03b3 release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis","volume":"20","author":"Zhou","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129097_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101815","article-title":"Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis","volume":"56","author":"Hamada","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:32:22Z","timestamp":1790537542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S0264410X26009060"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129097","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the influence of vaccine archetypes and epidemiological conditions on clinical trial metrics for tuberculosis vaccine candidates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129097"}}